 Actinium Pharmaceuticals Inc. NYSE: ATNM, a clinical-stage biopharmaceutical company, is developing antibody radiation-conjugates ARCs to combine the targeting ability of antibodies with the cell-killing ability of radiation. The Company is a leader in the targeted radiotherapy field for cancer patients who cant tolerate chemotherapy and radiation. 